Skip to main content

Pipeline

Our pipeline is built upon the broad therapeutic potential of our first-in-class therapeutic formulation, KLS1, to induce wtp53 and increase the tumor-suppressing T-cells activities, while reducing inflammation and oxidative stress. Each of our present product candidates is a derivative of KLS1.

IndicationDiscoveryPreclinicalPhase 1IND-ApplPhase 2Phase 3

Oncology

Cutaneous Melanoma *

Prostate Cancer *

Pancreatic Cancer *

Chronic Lymphocytic Leukemia *

B-16 Melanoma (Co-therapy w. Paclitaxel) **

B-16 Melanoma (Co-therapy w. Dacarbazine) **

B-16 Melanoma (Co-therapy w. Vinorelbine) **

B-16 Melanoma (Co-therapy w. Doxorubicin) **

B-16 Melanoma (Co-therapy w. Cisplatin) **

A-549 Lung Cancer **

HL-60 Leukemia **

SK-N-SH Neuroblastoma **

Merkel Cell Carcinoma (w. Pembrolizumab) **

Cutaneous Melanoma (w. Pembrolizumab) **

Cutaneous Melanoma *
DiscoveryPreclinicalIND-EnablPhase 1Phase 2Phase 3
Prostate Cancer *
DiscoveryPreclinicalPhase 1IND-ApplPhase 2Phase 3
Pancreatic Cancer *
DiscoveryPreclinicalPhase 1IND-ApplPhase 2Phase 3
Chronic Lymphocytic Leukemia *
DiscoveryPreclinicalPhase 1IND-ApplPhase 2Phase 3
B-16 Melanoma (Co-therapy w. Paclitaxel) **
DiscoveryPreclinicalPhase 1IND-ApplPhase 2Phase 3
B-16 Melanoma (Co-therapy w. Dacarbazine) **
DiscoveryPreclinicalPhase 1IND-ApplPhase 2Phase 3
B-16 Melanoma (Co-therapy w. Vinorelbine) **
DiscoveryPreclinicalPhase 1IND-ApplPhase 2Phase 3
B-16 Melanoma (Co-therapy w. Doxorubicin) **
DiscoveryPreclinicalPhase 1IND-ApplPhase 2Phase 3
B-16 Melanoma (Co-therapy w. Cisplatin) **
DiscoveryPreclinicalPhase 1IND-ApplPhase 2Phase 3
A-549 Lung Cancer **
DiscoveryPreclinicalPhase 1IND-ApplPhase 2Phase 3
HL-60 Leukemia **
DiscoveryPreclinicalPhase 1IND-ApplPhase 2Phase 3
SK-N-SH Neuroblastoma **
DiscoveryPreclinicalPhase 1IND-ApplPhase 2Phase 3
Merkel Cell Carcinoma (w. Pembrolizumab) **
DiscoveryPreclinicalPhase 1IND-ApplPhase 2Phase 3
Cutaneous Melanoma (w. Pembrolizumab) **
DiscoveryPreclinicalPhase 1IND-ApplPhase 2Phase 3

Next Milestone

* Patient recruitment in UA for Phase 1-2a. IND filing in the U.S. for Phase 2b.

** Entering into collaboration agreement with a Big Pharma company.

Pipeline Products

Learn more about our product development, research, and progress in developing our breakthrough therapies.

Clinical Phase 1
Preclinical Studies
Drug Discovery
Clinical Phase 1

KLS1 monotherapy

-

KLS1 monotherapy

-
Prostate Cancer

KLS1 monotherapy

-

KLS1 monotherapy

-
Preclinical Studies
Metastatic Breast Cancer

KLS1  combination therapy with Paclitaxel 

-
-
Ovarian Cancer

KLS1 combination therapy with Dacarbazine and Cisplatin

-
-
-
Drug Discovery
Cutaneous Melanoma

Combination therapy with Pembrolizumab and KLS1

-
Hodgkin Lymphoma

Combination therapy with Doxorubicin and KLS1

-
Merkel Cell Carcinoma

Combination therapy with Avelumab and KLS1 

-